Navigation Links
Candidate drug provides benefit in SMA animal models
Date:6/4/2013

In a new publication that appears in Human Molecular Genetics, the laboratory of Christine DiDonato, PhD reports on their pharmacological characterization of the drug RG3039, demonstrating that it can extend survival and improve function in two spinal muscular atrophy (SMA) mouse models. They have determined the minimum effective dose and drug action, thus contributing to dose selection and exposure estimates for the first studies with RG3039 in humans. As in cellular assays, the animal studies have shown that drug treatment leads to improvement in nuclear gem/Cajal body numbers in motor neurons. Gem loss is a cellular hallmark of fibroblasts derived from SMA patients; gem numbers inversely correlate with SMA disease severity. In addition, the laboratory has shown improved functional outcomes, including treadmill walking and gait dynamics, in animals receiving the drug. The laboratory has been testing RG3039 in SMA mouse models with disease phenotypes ranging from mild to severe.

The collective results suggest that RG3039 positively modifies motor unit pathologies and dysfunction, and that it may have therapeutic benefit for SMA.

Spinal muscular atrophy (SMA) is a devastating hereditary disease that is a leading cause of infant and early childhood mortality. Motor neurons in the spinal cord are affected, resulting in muscle weakness and in many cases breathing problems. SMA is caused by insufficient levels of the survival motor neuron (SMN) protein; depending on the level of SMN protein, patients may have mild to severe forms of SMA. There is currently no cure for the disease.

The goal of early SMA drug discovery programs has been to identify small molecules that induce the SMN gene to produce sufficient levels of protein to improve motor neuron functioning in affected patients. A promising drug candidate is RG3039, which has been shown to increase nuclear gem/Cajal body numbers in cellular assays.

Says DiDonato: "We are very happy that our research was able to assist in the pharmacological characterization of RG3039 and contribute to dose selection and exposure estimates for the first studies with RG3039 in human subjects. We are indebted to my colleague, Nancy Kuntz, MD, and co-author laboratories of Drs. Jasbir Singh and Mike Kiledjian along with Repligen and Families of Spinal Muscular Atrophy (FSMA), who initiated the development of this drug candidate. The depth of our manuscript would not have been possible without this group collaboration. Also, it is reassuring that our results of improved motor unit dysfunction in SMA mice treated with RG3039 mirror the independent findings by the laboratories of Drs. Sumner and Ko. Improved neuromuscular function is an obvious goal for SMA therapies. Thus, this drug candidate warrants further investigation. Overall, this SMA candidate drug is an exciting time as we take another step forward towards developing therapies for SMA patients."


'/>"/>

Contact: Peggy Murphy
pemurphy@luriechildrens.org
773-755-7485
Children's Memorial Hospital
Source:Eurekalert

Related medicine news :

1. Novel drug candidates offer new route to controlling inflammation
2. Presidential candidates should address childhood obesity and bullying, poll says
3. Parc at Piedmont - East Cobb to Host Candidate Forum for Primary Elections
4. New candidate drug stops cancer cells, regenerates nerve cells
5. BWH researchers discover new vaccine candidate for Pseudomonas aeruginosa
6. No Truth to Candidates Claim That Rape Hinders Pregnancy, Experts Say
7. New oral drug candidate for African sleeping sickness
8. Katon Direct, a Healthcare Micro-Marketing Solutions Company, Launches Their New Website, Innovating the way Healthcare Companies Find the Most Qualified Candidates
9. NIH-developed candidate dengue vaccine shows promise in early-stage trial
10. NIH-funded researchers begin trial of Shigella vaccine candidates
11. Drugs targeting blood vessels may be candidates for treating Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate and ... the benefits of making new water infrastructure a number one priority. “As we usher ... expect water infrastructure to become a top priority of our new political change agents.” ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... Crystallization in Process Chemistry by Applying Simple PAT Tools . , ... to isolate and purify the desired product. Chemists now spend more time ...
(Date:1/23/2017)... ... January 23, 2017 , ... "ProRandom is a set of camera tools that allow video editors ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... text with video footage. ProRandom works by using a virtual camera to create the ...
(Date:1/23/2017)... Atlanta, Georgia (PRWEB) , ... January 23, 2017 ... ... leader in providing high-quality general gynecological care and gynecological services for ... to providing personalized care for a wide variety of reproductive services from routine ...
(Date:1/23/2017)... ... January 23, 2017 , ... The ... at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities and individuals about ... been developed for use by nutrition educators and influencers within the public ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23, 2017 A new Transparency Market Research ... was valued at US$0.53 bn in 2013 and is predicted to ... CAGR between 2014 and 2022. The title of the report is ... Share, Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), also referred ...
(Date:1/23/2017)... SAN DIEGO and PALMA, ... Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical ... announced that the first patient has been enrolled ... of lead candidate, SNF472, for the treatment of ... haemodialysis (HD). Most ESRD patients, in ...
(Date:1/21/2017)... , Jan 20, 2017 Research and ... Laboratory Testing Market By Type of Test (Tumor, Clinical Chemistry, ... By Type of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), Forecast ... ... destination for healthcare services, market segments, especially clinical lab testing, ...
Breaking Medicine Technology: